Press Release: Sanofi’s Infilbray approved in the US as the first medicine to treat neurological manifestations of Type 3 Gaucher disease
Sanofi's Infilbray (venglustat) has been approved in the US to treat neurological symptoms of Type 3 Gaucher disease (GD3). The approval follows positive phase 3 study results showing significant improvements over existing therapy. Infilbray is the first oral treatment targeting neurological manifestations of GD3, a rare lysosomal storage disorder. Sanofi plans further global regulatory submissions.
How this was made

The 30-second read
Why it matters
The approval expands Sanofi's specialty care portfolio and provides a new revenue stream in a high‑unmet‑need area.
Market read
Regulatory approval is a material catalyst for Sanofi's stock and the rare‑disease biotech sector.
What to watch
Potential safety concerns (suicidal ideation, embryo‑fetal toxicity) could limit uptake.
Background
Sanofi announced FDA approval of Infilbray (venglustat), an oral glucosylceramide synthase inhibitor for neurological manifestations of Type 3 Gaucher disease.
Ticker impact
FDA approval of Infilbray for Type 3 Gaucher disease provides Sanofi a first‑in‑class therapy, likely boosting its specialty care revenue.
likely upward pressure as the market prices in new revenue potential
First‑time US approval of a novel oral GCS inhibitor for a rare disease, with breakthrough and orphan designations, creates a material growth catalyst.
Market effects
strengthens the rare‑disease biotech segment and may spur competitor pipelines.
benefits European and Asian markets where Sanofi has significant sales.
adds to the overall pipeline momentum for rare‑disease therapeutics worldwide.
Counterpoint
If pricing or reimbursement challenges arise, the stock may not rally as expected.
Key entities
- CompanySanofi
Global biopharma with US ticker SNY.
- DrugInfilbray
First oral therapy for GD3 neurological symptoms.


